Tazarotene: therapeutic strategies in the treatment of psoriasis, acne and photoaging.
Tazarotene is a member of the new generation of receptor-selective, synthetic retinoids for the topical treatment of mild to moderate plaque psoriasis, acne vulgaris and photoaging. Though they are effective in monotherapy, clinical studies with a focus on novel combination treatments and a comparison of different agents for these skin disorders are accumulating. The concomitant use of tazarotene with a mid-potency or high-potency corticosteroid enhances the efficacy in psoriatic plaques and reduces the risk of steroid-induced skin atrophy. Combining phototherapy with adjunctive tazarotene accelerates the clinical response and reduces the cumulative UVB or PUVA exposure load. Tazarotene applied once daily is superior to adapalene monotherapy in acne vulgaris and is efficacious in the treatment of photodamage. Novel therapeutic regimens such as short-contact therapy have been developed for both acne and psoriasis in order to diminish the major adverse events like pruritus, burning, local skin irritation and erythema.
Roeder
A
A
Klinik und Poliklinik für Dermatologie und Allergologie, Ludwig-Maximilians-Universität, Frauenlobstrasse 9-11, DE-80337 Munich, Germany. Alexander.Roeder@lrz.uni-muenchen.de
Schaller
M
M
Schäfer-Korting
M
M
Korting
H C
HC
D000152:Acne Vulgaris / Q000188:drug therapy*; D003879:Dermatologic Agents / Q000378:metabolism / Q000627:therapeutic use*; D005786:Gene Expression Regulation; D006801:Humans; D009539:Nicotinic Acids / Q000378:metabolism / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy*; D018168:Receptors, Retinoic Acid / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D012176:Retinoids / Q000378:metabolism / Q000627:therapeutic use*; D015595:Skin Aging / Q000187:drug effects*
D003879:Dermatologic Agents; D009539:Nicotinic Acids; D018168:Receptors, Retinoic Acid; D012176:Retinoids; C086827:tazarotene